Arrowhead Pharmaceuticals, Inc. (LON:0HI3)

Market Cap	6.26B
Revenue (ttm)	617.06M
Net Income (ttm)	-1.21M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,589
Average Volume	6,246
Open	65.00
Previous Close	60.97
Day's Range	65.00 - 69.38
52-Week Range	9.70 - 68.62
Beta	1.31
RSI	72.23
Earnings Date	Nov 26, 2025

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 711
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HI3

Financial Performance

In 2025, Arrowhead Pharmaceuticals's revenue was $829.45 million, an increase of 23258.15% compared to the previous year's $3.55 million. Losses were -$1.63 million, -99.73% less than in 2024.

Financial numbers in USD